

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 July 2022 (14.07.2022)



(10) International Publication Number
WO 2022/150507 A1

(51) International Patent Classification:

C12N 9/24 (2006.01) A61K 39/395 (2006.01)
C12N 15/09 (2006.01) A61K 39/44 (2006.01)
A01H 1/06 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2022/011487

(22) International Filing Date:

06 January 2022 (06.01.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/134,415 06 January 2021 (06.01.2021) US

(71) Applicant: **PALLEON PHARMACEUTICALS INC.**
[US/US]; 266 Second Avenue, 2nd Floor, Waltham, Mass-
achusetts 02451 (US).

(72) Inventors: **PENG, Li**; 6 Bicentennial Drive, Lexington,
Massachusetts 02421 (US). **XU, Lihui**; 58 Wolcott Road,
Chestnut Hill, Massachusetts 02467 (US). **TURNER, Au-
tumn**; c/o 266 Second Avenue, 2nd Floor, Waltham, Mass-
achusetts 02451 (US).

(74) Agent: **DAVENPORT, Andrew M.**; Goodwin Procter
LLP, 100 Northern Avenue, IP Docketing Dept/7th Floor,
Boston, Massachusetts 02210 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: SIALIDASE-PD-1-ANTIBODY FUSION PROTEINS AND METHODS OF USE THEREOF




FIGURE 1

(57) Abstract: The invention relates generally to recombinant sialidase and anti-PD-1 immunoglobulin antigen-binding domain fusion proteins. The invention also provides antibody conjugates including a sialidase and an anti-PD-1 antibody or a portion thereof. The invention further relates to methods of using the sialidase fusion proteins or antibody conjugates for treating cancer.

[Continued on next page]

WO 2022/150507 A1

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*